Botulinum toxin in motor disorders

Curr Opin Neurol. 1999 Aug;12(4):447-56. doi: 10.1097/00019052-199908000-00012.


Advances in the clinical use of botulinum neurotoxins continue. Of interest to the neurologist is the advanced practice in the treatment of focal dystonia and the new developments on other dyskinesias and on autonomic control of smooth muscle motility. New toxin serotypes are now being tested; their availability will improve clinical practice and will possibly lead to combined treatments. Indications in spasticity and in juvenile cerebral palsy are now under scrutiny. The combination of focal chemodenervation with specific rehabilitation procedures enables new development in this field.

Publication types

  • Review

MeSH terms

  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Dystonia / drug therapy*
  • Humans
  • Muscle Spasticity / drug therapy*
  • Neuromuscular Agents / pharmacology
  • Neuromuscular Agents / therapeutic use*


  • Neuromuscular Agents
  • Botulinum Toxins, Type A